LBI-0609

THERAPEUTIC AREA

SOLID TUMOR CANCER

LBI-0609

Indications:
Neuroendocrine, Lung, Pancreas, TNBC (Breast) Cancer
REGULATORY PATHWAY

505(b)(2) with improved formulation

TARGET INDICATION

Immediate release taxane based nanomedicine with first of its kind drug resistant sensitizer

CURRENT DEVELOPMENT STATUS

Active pre-clinical development

NEXT DEVELOPMENT PHASE

IND enabling study

TIME TO HUMAN BENEFIT

Human trials beginning in 1.5 to 2 years

IMMEDIATE FUNDING REQUIRED?

Yes, please inquire